In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Trevi Therapeutics Inc’s stock clocked out at $6.17, up 5.38% from its previous closing price of $5.86. In other words, the price has increased by $5.38 from its previous closing price. On the day, 1.6 million shares were traded. TRVI stock price reached its highest trading level at $6.335 during the session, while it also had its lowest trading level at $5.93.
Ratios:
To gain a deeper understanding of TRVI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.38 and its Current Ratio is at 15.38. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on July 01, 2025, initiated with a Overweight rating and assigned the stock a target price of $25.
On May 28, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $21.
Raymond James Upgraded its Outperform to Strong Buy on March 10, 2025, whereas the target price for the stock was revised from $9 to $29.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 25 ’25 when SCIASCIA THOMAS sold 2,631 shares for $6.60 per share. The transaction valued at 17,365 led to the insider holds 221,373 shares of the business.
GOOD JENNIFER L sold 5,263 shares of TRVI for $34,625 on Mar 21 ’25. The President & CEO now owns 213,313 shares after completing the transaction at $6.58 per share. On Mar 21 ’25, another insider, GOOD JENNIFER L, who serves as the Officer of the company, bought 5,263 shares for $6.58 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 751228352 and an Enterprise Value of 454243872.
Stock Price History:
The Beta on a monthly basis for TRVI is 0.57, which has changed by 1.1957295 over the last 52 weeks, in comparison to a change of 0.12153554 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $7.48, while it has fallen to a 52-week low of $2.36. The 50-Day Moving Average of the stock is -1.73%, while the 200-Day Moving Average is calculated to be 31.46%.
Shares Statistics:
It appears that TRVI traded 1.76M shares on average per day over the past three months and 1585220 shares per day over the past ten days. A total of 99.89M shares are outstanding, with a floating share count of 69.87M. Insiders hold about 41.36% of the company’s shares, while institutions hold 44.02% stake in the company. Shares short for TRVI as of 1749772800 were 7627036 with a Short Ratio of 4.34, compared to 1747267200 on 6869392. Therefore, it implies a Short% of Shares Outstanding of 7627036 and a Short% of Float of 7.26.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are keenly observing as 7.0 analysts analyze and rate the current performance of Trevi Therapeutics Inc (TRVI) in the stock market.The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.09 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.38 and -$0.51 for the fiscal current year, implying an average EPS of -$0.43. EPS for the following year is -$0.49, with 7.0 analysts recommending between -$0.26 and -$0.66.
